The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling

Clinical and Experimental Immunology

Volumn 185, Issue 3, 2016, Pages 361-371

  Roberts, A L ^a   Furnrohr B G ^a,b   Vyse, T J ^a   Rhodes, B ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

complement receptor 3; innate immunity; Leukadherin 1; NK cells; systemic lupus erythematosus

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT RECEPTOR AFFECTING AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKADHERIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOKINE; STAT5 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84983319992     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12803     Document Type: Article

References (41)

1. Ross GD, Vĕtvicka V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 1993; 92:181–4.
2. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 2009; 27:339–62.
3. Stockl J, Majdic O, Pickl WF, Rosenkranz A, Prager E, Gschwantler E, Knapp W. Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CDll b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored Fc gamma RlllB (CD16) molecules. J Immunol 1995; 5452–63.
4. Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 2010; 11:734–42.
5. Wang L, Gordon RA, Huynh L et al. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 2010; 32:518–30.
6. Ding C, Ma Y, Chen X et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun 2013; 4:2813.
7. Ling GS, Bennett J, Woollard KJ et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun 2014; 5:1–11.
8. Maiti AK, Kim-Howard X, Motghare P et al. Combined protein-and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM. Hum Mol Genet 2014; 23:4161–76.
9. Nath SK, Han S, Kim-Howard X et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; 40:152–4.
10. Han S, Kim-Howard X, Deshmukh H et al. Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Hum Mol Genet 2009; 18:1171–80.
11. MacPherson M, Lek HS, Prescott A, Fagerholm SC. A systemic lupus erythematosus-associated R77H substitution in the CD11b chain of the Mac-1 integrin compromises leukocyte adhesion and phagocytosis. J Biol Chem 2011; 286:17303–10.
12. Rhodes B, Fürnrohr BG, Roberts AL et al. The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann Rheum Dis 2012; 71:2028–34.
13. Fossati-Jimack L, Ling GS, Cortini A et al. Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells. PLOS ONE 2013; 8:e57082.
14. Zhou Y, Wu J, Kucik DF et al. Multiple lupus-associated ITGAM variants alter Mac-1 functions on neutrophils. Arthritis Rheum 2013; 65:2907–16.
15. Faridi MH, Maiguel D, Barth CJ et al. Identification of novel agonists of the integrin CD11b/CD18. Bioorg Med Chem Lett 2009; 19:6902–6.
16. Reed JH, Jain M, Lee K et al. Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem 2013; 288:9077–83.
17. Maiguel D, Faridi MH, Wei C et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal 2011; 4:ra57.
18. 22 integrin agonist improves chronic kidney allograft survival by reducing leukocyte recruitment and accompanying vasculopathy. Front Med 2014; 1:1–11.
19. Nelson MR, Tipney H, Painter JL et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015; 47:856–60.
20. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162:4511–20.
21. Strengell M, Matikainen S, Sirén J et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003; 170:5464–9.
22. Johnston JA, Bacon CM, Finbloom DS et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 1995; 92:8705–9.
23. Hervier B, Beziat V, Haroche J et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum 2011; 63:1698–706.
24. Eloranta ML, Lovgren T, Finke D et al. Regulation of the interferon-alpha production by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009; 2418–27.
25. Yuan D, Thet S, Zhou XJ, Wakeland EK, Dang T. The role of NK cells in the development of autoantibodies. Autoimmunity 2011; 44:641–51.
26. Mueller M, Barros P, Witherden AS et al. Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus. Am J Hum Genet 2013; 92:28–40.
27. Favilli F, Anzilotti C, Martinelli L et al. IL-18 activity in systemic lupus erythematosus. Ann N Y Acad Sci 2009; 1173:301–9.
28. Baranda L, de la Fuente H, Layseca-Espinosa E et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology 2005; 44:1507–13.
29. Carroll HP, Paunovic V, Gadina M. Signalling, inflammation and arthritis: crossed signals: the role of interleukin-15 and −18 in autoimmunity. Rheumatology 2008; 47:1269–77.
30. Yakubenko VP, Hsi LC, Cathcart MK, Bhattacharjee A. From macrophage interleukin-13 receptor to foam cell formation: mechanisms for αMβ2 integrin interference. J Biol Chem 2013; 288:2778–88.
31. Harley JB, Alarcón-Riquelme ME, Criswell LA et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40:204–10.
32. Keogan M, Kearns G, Caroline AJ. Extractable nuclear antigens and SLE: specificity and role in disease pathogenesis. In: Lahita R, Tsokos G, Buyon J, Koike T, eds. Systemic lupus erythematosus. San Diego, CA: Academic Press, 2011: 259–74.
33. Martin D, Elkon K. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med 2005; 202:1465–9.
34. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202:1575–85.
35. Philbin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans 2007; 35:1485–91.
36. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden J. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:1241–50.
37. Urbonaviciute V, Fürnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205:3007–18.
38. Wen Z, Xu L, Chen X et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 2013; 190:5411–22.
39. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous. Sci Rep 2015; 5:13886.
40. Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology 2012; 51:7–23.
41. Li J, Wang X, Zhang F, Yin H. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther 2013; 138:441–51.